The effect of migraine prophylaxis on migraine-related resource use and productivity.
In the US, it is estimated that up to 10% of men and 25% of women, particularly those aged 25-55 years, experience debilitating migraines, such that the condition presents an enormous economic burden for patients, health systems, employers and society. Migraine headache is a particularly prevalent condition associated with major reductions in patients' quality of life. From a payer perspective, the implementation of relevant programmes of migraine prophylaxis is highly desirable. Consistent evidence exists, from several randomized, controlled studies, of the efficacy of amitriptyline, divalproex sodium, propranolol, timolol and topiramate in migraine prophylaxis. Considering resource utilization, various studies suggest that migraine prophylaxis with antiepileptics, antidepressants, beta-blockers or calcium channel antagonists markedly reduces triptan use and visits to physician offices and emergency departments (EDs), without compromising quality of care or treatment outcomes. Over recent years, the effects of topiramate in reducing resource utilization in patients with migraine have been relatively widely studied. In US claims database analyses involving >4000 patients with migraine, topiramate significantly reduced triptan use by up to 20% in the 12-month period after starting treatment. Reductions were also noted in the numbers of ED visits, diagnostic procedures, hospital admissions and migraine-related hospitalization days. These long-term benefits of topiramate manifested without any increase in overall headache-related costs. Furthermore, in detailed modelling analyses based on UK and US data, topiramate-induced savings in acute medical services were estimated to offset about one-quarter of the monthly per patient cost of the topiramate regimen, which was shown to be a dominant cost-effective intervention relative to no preventive therapy: cost-effectiveness ratios were calculated as pound 5728 per quality-adjusted life-year (QALY) [2005 costings] and $US10 888 per QALY (2002 costings), respectively. Overall, there is a need to improve quality of care in migraine, and prophylactic therapy appears to be an effective option, particularly with respect to decreasing resource use and improving productivity. For both health-plan payers and employers, topiramate appears to be a cost-effective intervention for preventing migraine.
Láinez
Miguel J A
MJ
Department of Neurology, Hospital Clínico Universitario, Universidad de Valencia, 46010 Valencia, Spain. jlaineza@meditex.es
D000328:Adult; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D016208:Databases, Factual; D004526:Efficiency; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D000077236:Topiramate; D006113:United Kingdom / Q000453:epidemiology; D014481:United States / Q000453:epidemiology
D000077236:Topiramate; D005632:Fructose
J Manag Care Pharm. 2005 Mar;11(2):137-44
15766320
Headache. 2001 Jul-Aug;41(7):638-45
11554951
Clin Ter. 2000 May-Jun;151(3):145-8
10958046
Headache. 2005 Sep;45(8):1012-22
16109115
Headache. 2004 Nov-Dec;44(10):1050-5
15546274
Dis Manag. 2007 Jun;10(3):138-46
17590144
Curr Opin Neurol. 2008 Jun;21(3):309-15
18451715
Neurology. 2000 Sep 26;55(6):754-62
10993991
Headache. 1999 Oct;39(9):633-43
11284461
Neurology. 2008 Apr 22;70(17):1555-63
18427072
Clin Neuropharmacol. 2006 Sep-Oct;29(5):269-75
16960472
Expert Opin Pharmacother. 2007 Nov;8(16):2811-23
17956201
Clin Ther. 2005 Feb;27(2):154-65
15811478
Headache. 2003 Nov-Dec;43(10):1116-8; author reply 1118
14629251
Cochrane Database Syst Rev. 2004;(2):CD003225
15106196
Eur Neurol. 2007;58(4):215-7
17827966
Headache. 2007 Jul-Aug;47(7):1037-49
17635595
Headache. 2007 Apr;47(4):500-10
17445099
Headache. 1989 Jul;29(7):425-7
2668225
Headache. 2002 Nov-Dec;42(10):978-83
12453029
Arch Neurol. 2004 Apr;61(4):490-5
15096395
J Neurol. 2004 Aug;251(8):943-50
15316798
Cephalalgia. 2006 Dec;26(12):1473-82
17116098
Neurol Sci. 2004 Dec;25(5):245-50
15624081
J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1730-2
16291905
Arch Intern Med. 1999 Apr 26;159(8):813-8
10219926
Curr Med Res Opin. 2004 Nov;20(11):1805-14
15537481
Headache. 1998 Feb;38(2):87-96
9529763
Headache. 2001 Feb;41(2):119-28
11251695
Pharmacoeconomics. 1997;11 Suppl 1:1-10
10168038
J Headache Pain. 2007 Oct;8(5):283-8
17955167
Expert Opin Emerg Drugs. 2006 Sep;11(3):419-27
16939382
Cochrane Database Syst Rev. 2004;(3):CD003226
15266476
Headache. 2003 Jun;43(6):621-7
12786921
Dis Manag. 2005 Dec;8(6):382-91
16351556
JAMA. 2006 Apr 19;295(15):1824-30
16622144
Expert Opin Pharmacother. 2007 Dec;8(17):3029-33
18001261
Cephalalgia. 2002 Apr;22(3):209-21
12047461
Arch Neurol. 1997 Sep;54(9):1141-5
9311358
Neurology. 2002 Mar 26;58(6):885-94
11914403
Am J Manag Care. 2005 Jun;11(2 Suppl):S62-7
16095269
Headache. 2006 Oct;46 Suppl 2:S61-8
17044843
Neurology. 2004 Jul 27;63(2):261-9
15277618
Cephalalgia. 1998 Nov;18(9):605-11
9876883
Headache. 2003 Mar;43(3):171-8
12603635
Am Fam Physician. 2002 Dec 1;66(11):2123-30
12484694
Expert Opin Pharmacother. 2007 Aug;8(11):1605-13
17685879
Headache. 2007 Apr;47 Suppl 1:S52-7
17425710
Headache. 2004 Nov-Dec;44(10):1024-8
15546267
J Neurol. 2004 Feb;251 Suppl 1:I8-11
14991336
Am J Health Syst Pharm. 2007 Jul 15;64(14):1483-91
17617498
Cleve Clin J Med. 2006 Sep;73(9):793-4, 797, 800-1 passim
16970133